Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

PMID:
29074604
2.

A method to reduce ancestry related germline false positives in tumor only somatic variant calling.

Halperin RF, Carpten JD, Manojlovic Z, Aldrich J, Keats J, Byron S, Liang WS, Russell M, Enriquez D, Claasen A, Cherni I, Awuah B, Oppong J, Wicha MS, Newman LA, Jaigge E, Kim S, Craig DW.

BMC Med Genomics. 2017 Oct 19;10(1):61. doi: 10.1186/s12920-017-0296-8.

3.

A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.

Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG.

PLoS One. 2017 Jun 6;12(6):e0179170. doi: 10.1371/journal.pone.0179170. eCollection 2017.

4.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

5.

The role and safe use of the ambulatory syringe pump in palliative and end-of-life care.

Armstrong M, Byron S, Hamill C.

Int J Palliat Nurs. 2017 Mar 16;23(3):108-110. doi: 10.12968/ijpn.2017.23.3.108. No abstract available.

PMID:
28345470
6.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.

Gynecol Oncol. 2017 May;145(2):366-373. doi: 10.1016/j.ygyno.2017.02.031. Epub 2017 Mar 15.

PMID:
28314589
7.

Supporting Human Papillomavirus Vaccination in Adolescents: Perspectives From Commercial and Medicaid Health Plans.

Ng JH, Sobel K, Roth L, Byron SC, Lindley MC, Stokley S.

J Public Health Manag Pract. 2017 May/Jun;23(3):283-290. doi: 10.1097/PHH.0000000000000440.

PMID:
27798527
8.

Translating RNA sequencing into clinical diagnostics: opportunities and challenges.

Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW.

Nat Rev Genet. 2016 May;17(5):257-71. doi: 10.1038/nrg.2016.10. Epub 2016 Mar 21. Review.

PMID:
26996076
9.

Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer.

Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D.

PLoS One. 2016 Mar 18;11(3):e0150564. doi: 10.1371/journal.pone.0150564. eCollection 2016.

10.

Access to Psychosocial Services Prior to Starting Antipsychotic Treatment Among Medicaid-Insured Youth.

Finnerty M, Neese-Todd S, Pritam R, Leckman-Westin E, Bilder S, Byron SC, Hudson Scholle S, Crystal S, Olfson M.

J Am Acad Child Adolesc Psychiatry. 2016 Jan;55(1):69-76.e3. doi: 10.1016/j.jaac.2015.09.020. Epub 2015 Oct 14.

11.

Human Papillomavirus Vaccination Coverage Among Female Adolescents in Managed Care Plans - United States, 2013.

Ng J, Ye F, Roth L, Sobel K, Byron S, Barton M, Lindley M, Stokley S.

MMWR Morb Mortal Wkly Rep. 2015 Oct 30;64(42):1185-9. doi: 10.15585/mmwr.mm6442a1.

12.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

13.

Research in the osteopathic medical profession: roadmap to recovery-conundrums in osteopathic research require consensus and collaboration.

Walkowski SA, Eland DC, Hain S, Byron S.

J Am Osteopath Assoc. 2015 Feb;115(2):70-1. doi: 10.7556/jaoa.2015.016. No abstract available.

14.

An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.

Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, Tembe W, Keifer JA, Corneveaux JJ, Byron SA, Forman KM, Zuccaro C, Keats JJ, Lorusso PM, Carpten JD, Trent JM, Craig DW.

Pac Symp Biocomput. 2015:56-67.

15.

Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.

Mould AP, Craig SE, Byron SK, Humphries MJ, Jowitt TA.

Biochem J. 2014 Dec 15;464(3):301-13. doi: 10.1042/BJ20141047.

PMID:
25333419
16.

Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway.

Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT.

Oncotarget. 2014 Oct 15;5(19):9382-95.

17.

Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines.

Kealey E, Scholle SH, Byron SC, Hoagwood K, Leckman-Westin E, Kelleher K, Finnerty M.

Acad Pediatr. 2014 Sep-Oct;14(5 Suppl):S68-75. doi: 10.1016/j.acap.2014.05.009. Review.

18.

Developing measures for pediatric quality: methods and experiences of the CHIPRA pediatric quality measures program grantees.

Byron SC, Gardner W, Kleinman LC, Mangione-Smith R, Moon J, Sachdeva R, Schuster MA, Freed GL, Smith G, Scholle SH.

Acad Pediatr. 2014 Sep-Oct;14(5 Suppl):S27-32. doi: 10.1016/j.acap.2014.06.013.

PMID:
25169454
19.

Variations in measurement of sexual activity based on EHR definitions.

Berlan ED, Ireland AM, Morton S, Byron SC, Canan BD, Kelleher KJ.

Pediatrics. 2014 May;133(5):e1305-12. doi: 10.1542/peds.2013-3232. Epub 2014 Apr 14.

20.

The Health Technology Assessment of companion diagnostics: experience of NICE.

Byron SK, Crabb N, George E, Marlow M, Newland A.

Clin Cancer Res. 2014 Mar 15;20(6):1469-76. doi: 10.1158/1078-0432.CCR-13-1955.

21.

Using computer-extracted data from electronic health records to measure the quality of adolescent well-care.

Gardner W, Morton S, Byron SC, Tinoco A, Canan BD, Leonhart K, Kong V, Scholle SH.

Health Serv Res. 2014 Aug;49(4):1226-48. doi: 10.1111/1475-6773.12159. Epub 2014 Jan 29.

22.

Implementing the 'verification of expected death' policy in clinical practice.

Byron S, Hoskins R.

Br J Community Nurs. 2013 Oct;18(10):505-6, 508-11.

PMID:
24471218
23.

Evidence for the management of adolescent depression.

Lewandowski RE, Acri MC, Hoagwood KE, Olfson M, Clarke G, Gardner W, Scholle SH, Byron S, Kelleher K, Pincus HA, Frank S, Horwitz SM.

Pediatrics. 2013 Oct;132(4):e996-e1009. doi: 10.1542/peds.2013-0600. Epub 2013 Sep 16. Review.

24.

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.

Neoplasia. 2013 Aug;15(8):975-88.

25.

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Byron SA, Loch DC, Pollock PM.

Int J Gynecol Cancer. 2012 Nov;22(9):1517-26. doi: 10.1097/IGC.0b013e31826f6806.

PMID:
23060048
26.

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.

Doudican NA, Byron SA, Pollock PM, Orlow SJ.

Anticancer Drugs. 2013 Feb;24(2):181-8. doi: 10.1097/CAD.0b013e32835a43f1.

PMID:
23059386
27.

Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer.

Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S.

PLoS One. 2012;7(10):e46823. doi: 10.1371/journal.pone.0046823. Epub 2012 Oct 4.

28.

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM.

Mol Cancer. 2012 Oct 5;11:75. doi: 10.1186/1476-4598-11-75.

29.

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM.

PLoS One. 2012;7(2):e30801. doi: 10.1371/journal.pone.0030801. Epub 2012 Feb 23. Erratum in: PLoS One. 2012;7(2):doi/10.1371/annotation/0bfaecca-0f87-43fe-97cc-f2ae3ddeb6d5.

30.

Reducing disparities and improving quality: understanding the needs of small primary care practices.

Weinick RM, Byron SC, Han ES, French JB, Scholle SH.

Ethn Dis. 2010 Winter;20(1):58-63.

PMID:
20178184
31.

FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM.

Gynecol Oncol. 2010 Apr;117(1):125-9. doi: 10.1016/j.ygyno.2009.12.002. Epub 2010 Jan 27.

PMID:
20106510
32.

Variation in outpatient antibiotic prescribing in the United States.

Steinman MA, Yang KY, Byron SC, Maselli JH, Gonzales R.

Am J Manag Care. 2009 Dec;15(12):861-8.

33.

Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix.

Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA, Pollock PM, Mohammadi M.

Mol Cell Biol. 2009 Sep;29(17):4663-78. doi: 10.1128/MCB.01780-08. Epub 2009 Jun 29.

34.

FGFR2 as a molecular target in endometrial cancer.

Byron SA, Pollock PM.

Future Oncol. 2009 Feb;5(1):27-32. doi: 10.2217/14796694.5.1.27. Review.

PMID:
19243295
35.

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, Curtin JA, Hyder P, Harper UL, Riedesel E, Mann GJ, Trent JM, Bastian BC, Meltzer PS, Mohammadi M, Pollock PM.

Mol Cancer Res. 2009 Jan;7(1):41-54. doi: 10.1158/1541-7786.MCR-08-0021.

36.

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.

Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.

Clin Cancer Res. 2008 Oct 1;14(19):6146-53. doi: 10.1158/1078-0432.CCR-08-0509.

37.

Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.

Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D.

Mol Cancer Res. 2008 Sep;6(9):1491-8. doi: 10.1158/1541-7786.MCR-07-2173.

38.

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.

Cancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770. Erratum in: Cancer Res. 2008 Dec 1;68(23):10005.

39.

Macmillan nurse facilitators: conducting a training needs assessment for district nurses.

O'Hara A, Byron S, Moriarty D.

Int J Palliat Nurs. 2007 Dec;13(12):598-604.

PMID:
18399385
40.

Macmillan nurse facilitators: establishing a palliative resource nurse network in primary care.

Byron S, Moriarty D, O'Hara A.

Int J Palliat Nurs. 2007 Sep;13(9):438-44.

PMID:
18026062
41.

Macmillan nurse facilitators for palliative care: evaluation of a pilot project.

Moriarty D, O'Hara A, Byron S.

Int J Palliat Nurs. 2007 Jul;13(7):334-43.

PMID:
17851377
42.

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D.

Br J Cancer. 2006 Nov 6;95(9):1220-8. Epub 2006 Oct 17.

43.

Who can't pay for health care?

Weinick RM, Byron SC, Bierman AS.

J Gen Intern Med. 2005 Jun;20(6):504-9.

44.

Federal sponsorship of cost-effectiveness and related research in health care: 1997-2001.

Siegel JE, Byron SC, Lawrence WF.

Value Health. 2005 May-Jun;8(3):223-36.

45.

Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer.

Byron SA, Yee D.

Semin Oncol. 2003 Oct;30(5 Suppl 16):125-32. Review.

PMID:
14613033
46.

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI.

J Clin Pharmacol. 2003 Apr;43(4):414-22.

PMID:
12723462
47.

Fracture mechanics. A comparison study of torsional stress on bone.

VanCourt RB, Byron SE, Ali SJ, Caldwell BD.

J Am Podiatr Med Assoc. 2000 Apr;90(4):167-74.

PMID:
10800270
48.
49.

Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women.

Whittingham S, Byron SL, Tuomilehto J, Zimmet PZ, Myers MA, Vidgren G, Rowley MJ, Feeney SJ, Koskela P, Tuomilehto-Wolf E, Mackay IR.

Diabet Med. 1997 Aug;14(8):678-85.

PMID:
9272595
50.

Autoantibodies to M2 mitochondrial autoantigens in normal human sera by immunofluorescence and novel assays.

Omagari K, Rowley MJ, Whittingham S, Jois JA, Byron SL, Mackay IR.

J Gastroenterol Hepatol. 1996 Jul;11(7):610-6.

PMID:
8840233

Supplemental Content

Support Center